Sphere Fluidics Introduces New Cyto-Mine Studio Software Suite

CAMBRIDGE, England–(BUSINESS WIRE)–Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced Cyto-Mine^® Studio Software Suite, an updated software for its innovative Cyto-Mine Single Cell Analysis System. The software works alongside industry-standard robotic platforms and corporate databases to improve antibody discovery and cell line development workflows.

Sphere Fluidics’ Cyto-Mine is an automated platform which integrates single cell screening, sorting, isolation and clone verification. Its Cyto-Mine Studio Software Suite has updated features and user interfaces for the Cyto-Mine Instrument Control Software and the off-line Cyto-Mine Data Analysis Software. It has an application programming interface (API) that enables easy communication with many industry-standard robotic platforms and links to corporate databases for easy data transfer, and includes features such as single cell dispensing to individual wells of 96- and 384-well microtiter plates and software data outputs from single cell imaging analysis.

Dr Rob Marchmont, Director of Sales and Marketing, Sphere Fluidics, said: “Developed with feedback from Sphere Fluidics’ customers, the new software has user-friendly and intuitive navigation, is secure and has programming features to allow scientists to easily monitor and run industry-standard workflows to find new rare antibody-producing cells and high-expressing cells from CHO cell lines or transfection pools. We are now updating our installed systems in Asia, Europe and the US with favorable customer feedback.”

Dr Marian Rehak, Director of R&D, Sphere Fluidics, said: “The new software is robust and brings updated features to the Cyto-Mine platform, providing high-throughput single cell analysis and monoclonality assurance for antibody discovery and cell line development. Cyto-Mine can process small numbers (e.g. a hundred thousand) of cells for monoclonality assurance through to 40 million cells for high-throughput antibody discovery. Inclusion of single cell imaging at various check points and data outputs is particularly powerful for monoclonality assurance.”

For more information about Sphere Fluidics and Cyto-Mine, please visit: https://www.spherefluidics.com/products/integrated-systems/cyto-mine/